Zacks Investment Research upgraded shares of Transcat (NASDAQ:TRNS) from a hold rating to a buy rating in a report published on Saturday, February 3rd. They currently have $18.00 price target on the scientific and technical instruments company’s stock.
According to Zacks, “Transcat, Inc. distributes test and measurement instruments and provides accredited calibration services to a variety of industries including life sciences, pharmaceutical, petroleum refining, chemical manufacturing, public utility, pulp and paper, communications, automotive and aerospace. “
Separately, Singular Research began coverage on shares of Transcat in a report on Wednesday, November 15th. They issued a buy rating and a $15.30 target price for the company.
Transcat (TRNS) opened at $15.72 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.38 and a debt-to-equity ratio of 0.50. Transcat has a twelve month low of $11.02 and a twelve month high of $16.49. The company has a market cap of $111.94, a P/E ratio of 23.12, a price-to-earnings-growth ratio of 2.96 and a beta of 0.40.
Transcat (NASDAQ:TRNS) last posted its quarterly earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.12 by $0.09. Transcat had a net margin of 3.24% and a return on equity of 10.03%. The company had revenue of $40.48 million during the quarter. equities analysts forecast that Transcat will post 0.66 earnings per share for the current fiscal year.
In other news, Director John T. Smith sold 2,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.70, for a total value of $31,400.00. Following the completion of the transaction, the director now owns 33,100 shares in the company, valued at approximately $519,670. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 8.80% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. QCI Asset Management Inc. NY boosted its stake in Transcat by 62.8% during the 4th quarter. QCI Asset Management Inc. NY now owns 52,467 shares of the scientific and technical instruments company’s stock worth $748,000 after purchasing an additional 20,233 shares during the period. Wedge Capital Management L L P NC acquired a new stake in Transcat during the 4th quarter worth $378,000. Dimensional Fund Advisors LP boosted its stake in Transcat by 3.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 290,146 shares of the scientific and technical instruments company’s stock worth $3,960,000 after purchasing an additional 8,771 shares during the period. Ameriprise Financial Inc. acquired a new stake in Transcat during the 3rd quarter worth $2,484,000. Finally, Quantum Capital Management acquired a new stake in Transcat during the 3rd quarter worth $696,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Transcat (NASDAQ:TRNS) Stock Rating Upgraded by Zacks Investment Research” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/13/transcat-trns-upgraded-at-zacks-investment-research-2.html.
Transcat Company Profile
Transcat, Inc is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak).
Get a free copy of the Zacks research report on Transcat (TRNS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.